A Phase 3 interventional study of liraglutide and liraglutide in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 120 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 3, and was the 15th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Second Xiangya Hospital of Central South University · Sites in China
Ages 18+
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 12 · Phase 4 3
First in 2012; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 835 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 32 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 32 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 6th largest by enrollment of the 149 interventional ones that give a count, is one of 8 that started in 2014, is one of 54 in phase 3, and was the 174th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 835 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: liraglutide
Drug: liraglutide
Drug: placebo
Drug: placebo
Drug: placebo
Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
Change From Baseline in Glycosylated Haemoglobin (HbA1c)
Change from baseline in glycosylated haemoglobin (HbA1c), after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.
Time frame: Week 0, Week 26
Change From Baseline in Body Weight
Change from baseline body weight, after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.
Time frame: Week 0, Week 26
Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes
Number of treatment-emergent symptomatic hypoglycaemic episodes during 26 weeks of treatment. Symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or a self-measured plasma glucose (SMPG) value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification is defined as an episode that required assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions.
Time frame: Weeks 0-26
Subjects were randomised at 113 sites in 13 countries: Austria 2 sites, Belgium 9 sites, Bulgaria 5 sites, Canada 9 sites, Denmark 4 sites, Finland 6 sites, France 9 sites, Italy 7 sites, Netherlands 5 sites, South Africa 2 sites, Spain 5 sites, Sweden 5 sites, United States 45 sites.
| Milestone | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo |
|---|---|---|---|---|
| Started | 212 | 209 | 207 | 207 |
| Exposed | 211 | 209 | 206 | 206 |
| Completed | 186 | 177 | 165 | 180 |
| Not completed | 26 | 32 | 42 | 27 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 7 |
| Withdrew: Withdrawal by subject | 10 | 10 | 5 | 13 |
| Withdrew: Adverse event | 12 | 19 | 34 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 3 |
| Withdrew: Unclassified | 0 | 0 | 3 | 2 |
Change from baseline in glycosylated haemoglobin (HbA1c), after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.
| Percent (%) glycosylated haemoglobin | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo |
|---|---|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin (HbA1c) | -0.23 ± 0.744 | -0.23 ± 0.731 | -0.32 ± 0.73 | 0.01 ± 0.674 |
Change from baseline body weight, after 26 weeks of treatment. Full analysis set (FAS = 831) included all randomised subjects who had received at least one dose and had any post-randomisation data.
| kg | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -2.37 ± 3.015 | -4.03 ± 3.677 | -5.1 ± 3.787 | -0.26 ± 2.782 |
Number of treatment-emergent symptomatic hypoglycaemic episodes during 26 weeks of treatment. Symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or a self-measured plasma glucose (SMPG) value of \<3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification is defined as an episode that required assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions.
| episodes | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo |
|---|---|---|---|---|
| Number of Treatment-emergent Symptomatic Hypoglycaemic Episodes | 1437 | 1943 | 1490 | 1567 |
Collected over From the first day of exposure to randomised treatment (week 0) to 7 days after the last day of randomised treatment (week 26).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 0.6 mg | — | 20/211 (9.5%) | 137/211 (64.9%) |
| Liraglutide 1.2 mg | — | 21/209 (10%) | 164/209 (78.5%) |
| Liraglutide 1.8 mg | — | 14/206 (6.8%) | 162/206 (78.6%) |
| Liraglutide Placebo | — | 14/206 (6.8%) | 125/206 (60.7%) |
| Event | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo |
|---|---|---|---|---|
| Hypoglycaemic unconsciousnessNervous system disorders | 3/211 | 6/209 | 2/206 | 1/206 |
| HypoglycaemiaMetabolism and nutrition disorders | 5/211 | 2/209 | 1/206 | 1/206 |
| Coronary artery diseaseCardiac disorders | 0/211 | 0/209 | 0/206 | 2/206 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/211 | 0/209 | 2/206 | 2/206 |
| DiarrhoeaGastrointestinal disorders | 0/211 | 2/209 | 0/206 | 0/206 |
| VomitingGastrointestinal disorders | 0/211 | 2/209 | 0/206 | 1/206 |
| Myocardial infarctionCardiac disorders | 0/211 | 0/209 | 0/206 | 1/206 |
| VolvulusGastrointestinal disorders | 0/211 | 0/209 | 1/206 | 0/206 |
| Chest painGeneral disorders | 0/211 | 0/209 | 1/206 | 0/206 |
| Non-cardiac chest painGeneral disorders | 0/211 | 0/209 | 0/206 | 1/206 |
| Event | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 68/211 | 97/209 | 102/206 | 34/206 |
| Decreased appetiteMetabolism and nutrition disorders | 21/211 | 40/209 | 50/206 | 9/206 |
| NasopharyngitisInfections and infestations | 44/211 | 40/209 | 47/206 | 46/206 |
| VomitingGastrointestinal disorders | 19/211 | 29/209 | 35/206 | 7/206 |
| DiarrhoeaGastrointestinal disorders | 14/211 | 25/209 | 30/206 | 17/206 |
| HeadacheNervous system disorders | 16/211 | 26/209 | 30/206 | 30/206 |
| Upper respiratory tract infectionInfections and infestations | 14/211 | 11/209 | 11/206 | 25/206 |
| DyspepsiaGastrointestinal disorders | 8/211 | 19/209 | 24/206 | 1/206 |
| ConstipationGastrointestinal disorders | 6/211 | 23/209 | 14/206 | 9/206 |
| FatigueGeneral disorders | 13/211 | 17/209 | 22/206 | 3/206 |
Baseline (BL) characteristics were presented for full analysis set (FAS = 831 subjects). Out of 835 randomised subjects, 4 were excluded from FAS:1 subject each in the lira 1.8 mg, 0.6 mg and placebo arm were not exposed to trial treatment and 1 subject in the lira 1.8 mg arm had no post-BL measurements.
| Age, Continuous(years) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo | Total |
|---|---|---|---|---|---|
| Mean | 43.9 ± 12.88 | 42.8 ± 13.31 | 43.2 ± 12.9 | 42.7 ± 12.97 | 43.2 ± 13.00 |
| Gender(Participants) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo | Total |
|---|---|---|---|---|---|
| Female | 118 | 106 | 113 | 112 | 449 |
| Male | 93 | 103 | 92 | 94 | 382 |
| Glycosylated Haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo | Total |
|---|---|---|---|---|---|
| Mean | 8.09 ± 0.743 | 8.07 ± 0.731 | 8.04 ± 0.736 | 8.12 ± 0.723 | 8.08 ± 0.732 |
| Body Weight(kg) | Liraglutide 0.6 mg | Liraglutide 1.2 mg | Liraglutide 1.8 mg | Liraglutide Placebo | Total |
|---|---|---|---|---|---|
| Mean | 83.10 ± 16.137 | 84.69 ± 18.155 | 83.64 ± 17.620 | 84.20 ± 16.539 | 83.91 ± 17.109 |
Showing the first 100 of 120 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of May 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide